HomeInsightsPE

Aurobindo Pharma Ltd PE Ratio

Aurobindo Pharma Ltd PE Ratio

stocks purchased

₹ 4.1 Cr

Volume Transacted

(Dec 13, 2024)

stocks purchased

34.2 K

Stocks Traded

(Dec 13, 2024)

Last Updated on: Dec 14, 2024

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

PE

19.4

Last updated on: Dec 14, 2024

Key Highlights

  • The P/E Ratio of Aurobindo Pharma Ltd is 19.4 as of 14 Dec 9.00 AM .
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 19.5 on March 2019 to 20.1 on March 2024 . This represents a CAGR of 0.51% over 6 years.
  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1207 as of 13 Dec 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Aurobindo Pharma Ltd

No data available

Company Fundamentals for Aurobindo Pharma Ltd

No data available

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

Share Price

₹ 1207.95

-7.20 (-0.59%)

stock direction

Last updated on: Dec 13, 2024

Market Price of Aurobindo Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Aurobindo Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
13 Dec 20241207.95
12 Dec 20241215.15
11 Dec 20241225.7
10 Dec 20241238.05
09 Dec 20241239.4
06 Dec 20241245.85
05 Dec 20241243.7
04 Dec 20241258.05
03 Dec 20241266.25
02 Dec 20241255.25

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Aurobindo Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Aurobindo Pharma Ltd1970,778
Sun Pharmaceuticals Industries Ltd384,35,179
Divis Laboratories Ltd851,55,995
Cipla Ltd251,16,890
Torrent Pharmaceuticals Ltd651,13,295
Mankind Pharma Ltd501,05,787

Key Valuation Metric of Aurobindo Pharma Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Revenue of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Dividend Payout of Aurobindo Pharma Ltd

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma tumbles after US FDA issues warning letter to Telangana unit

In May 2024, the United States Food and Drug Administration (US FDA) had conducted an insp...

Read more

2024-08-16 00:00:00

News

Eugia Pharma Specialities receives USFDA warning for Unit III

Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugi...

Read more

2024-08-16 00:00:00

News

Aurobindo Pharma consolidated net profit rises 61.05% in the June 2024 quarter

Net profit of Aurobindo Pharma rose 61.05% to Rs 919.22 crore in the quarter ended June 20...

Read more

2024-08-12 00:00:00

News

Auro Pharma gets USFDA nod for atrophic vaginitis drug

The approved drug is bioequivalent and therapeutically equivalent to the reference listed ...

Read more

2024-08-07 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Aurobindo Pharma Ltd

What is the current PE Ratio of Aurobindo Pharma Ltd?

The Current PE Ratio of Aurobindo Pharma Ltd is 19.41 as on 14 Dec 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 14 Dec 2024.

What was the PE Ratio of Aurobindo Pharma Ltd last year?

The PE Ratio of Aurobindo Pharma Ltd was 15.74 last year, now the PE ratio is 19.41, showing a year-on-year growth of 23.3%.

What does the PE Ratio of Aurobindo Pharma Ltd indicate about its stock?

The PE Ratio of Aurobindo Pharma Ltd is 19.41. This ratio indicates that investors are willing to pay 19.41 times the earnings per share for each share of Aurobindo Pharma Ltd.

What is the PE Ratio Growth of Aurobindo Pharma Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Aurobindo Pharma Ltd grew by 23.3% whereas, the EPS ratio grew by -10.8.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions